These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E, Global Antifungal Surveillance Study. J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797 [Abstract] [Full Text] [Related]
3. CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures. Tan GL, Peterson EM. J Clin Microbiol; 2005 Apr; 43(4):1727-31. PubMed ID: 15814992 [Abstract] [Full Text] [Related]
4. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Quindós G, Sánchez-Vargas LO, Villar-Vidal M, Eraso E, Alkorta M, Hernández-Almaraz JL. Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468 [Abstract] [Full Text] [Related]
11. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. Lee SC, Lo HJ, Fung CP, Lee N, See LC. J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647 [Abstract] [Full Text] [Related]
12. In vitro activity of voriconazole against Candida species isolated in Taiwan. Yang YL, Cheng HH, Lo HJ. Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436 [Abstract] [Full Text] [Related]
13. Susceptibility of Candida species to fluconazole assayed by a disk diffusion method with automated reading versus a microdilution method. Finquelievich JL, Iovannitti CA, Mujica MT, Relloso S, Carnovale S, de Elías Costa MR, Jewtuchowicz V, Espinel-Ingroff A. Rev Argent Microbiol; 2003 Sep; 35(4):214-8. PubMed ID: 14976874 [Abstract] [Full Text] [Related]
15. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT. Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [Abstract] [Full Text] [Related]
16. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N. Mycoses; 2007 Jan; 50(1):52-7. PubMed ID: 17302749 [Abstract] [Full Text] [Related]
19. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Gualco L, Debbia EA, Bandettini R, Pescetto L, Cavallero A, Ossi MC, Schito AM, Marchese A. Int J Antimicrob Agents; 2007 Feb; 29(2):179-84. PubMed ID: 17175140 [Abstract] [Full Text] [Related]